title: BCG vaccination and the prevalence of latent tuberculosis infection in an aboriginal population.
abstract: METHODS
  Estimations of prevalence of latent tuberculous infection (LTBI) are confounded by factors known to influence the results of the tuberculin skin test (TST) such as age, contact history and bacille Calmette-Guerin (BCG) vaccination. Appropriate interpretation of TST results is necessary to ensure LTBI treatment for those at greatest risk.
  
  
  OBJECTIVE
  To document the prevalence of LTBI in Aboriginal people living on a reserve in British Columbia (BC) and to determine the influence of BCG.
  
  
  METHODS
  A population-based, retrospective descriptive analysis of all epidemiological data collected for the on-reserve Aboriginal programme in BC (1951-1996).
  
  
  RESULTS
  Of 17615 persons who received a TST during the study period, 42% had received BCG. During the study period, an average of 2517 TSTs were completed per year (SD = 1228) among persons with an average age of 26 years (SD = 16). Among all subjects, the average prevalence of LTBI was 25% (95 %CI 24-25). The presence of BCG (OR = 3.1, 95%CI 2.8-3.4) and multiple BCGs (OR = 10.2, 95%CI 7.7-13.6) were both associated with a positive TST. A positive TST was also associated with a shorter duration in years between the most recent BCG and the TST.
  
  
  CONCLUSIONS
  The average prevalence of LTBI in a sequential sample of Aboriginal people living on a reserve in BC was estimated at 25%. BCG, especially in multiple doses, increased the likelihood of a positive TST.
authors.affiliation: Department of Tuberculosis Control, British Columbia Centre for Disease Control (BCCDC), Vancouver, Canada. victoria.cook@bccdc.ca
authors.forename: V J
authors.initials: VJ
authors.lastname: Cook
authors.forename: L
authors.initials: L
authors.lastname: Kuramoto
authors.forename: K
authors.initials: K
authors.lastname: Noertjojo
authors.forename: R K
authors.initials: RK
authors.lastname: Elwood
authors.forename: J M
authors.initials: JM
authors.lastname: Fitzgerald
mesh_terms: D000293:Adolescent; D000328:Adult; D001500:BCG Vaccine / Q000627:therapeutic use*; D001955:British Columbia / Q000453:epidemiology; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011153:Population; D015995:Prevalence; D012189:Retrospective Studies; D014374:Tuberculin Test; D014397:Tuberculosis, Pulmonary / Q000453:epidemiology* / Q000517:prevention & control*; D014611:Vaccination
chemical_list: D001500:BCG Vaccine